Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05946785 · ClinicalTrials.gov registry record · Early Phase 1
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes
A Early Phase 1 study of Gestational Diabetes and Vascular Endothelial Function, sponsored by Anna Stanhewicz, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT05946785: Recruiting Early Phase 1 study of Gestational Diabetes and Vascular Endothelial Function, sponsored by Anna Stanhewicz, PhD.
NCT05946785 is a Early Phase 1 study of Gestational Diabetes and Vascular Endothelial Function that is actively recruiting participants, run by Anna Stanhewicz, PhD. The registered enrollment target is 28 participants, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05946785, a Early Phase 1 study of Gestational Diabetes and Vascular Endothelial Function, is actively recruiting participants, sponsored by Anna Stanhewicz, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigation is to examine the role of oxidative stress in aberrant microvascular function in otherwise healthy women with a history of GDM.
Primary Outcome
cutaneous vascular vasodilator responses to acetylcholine perfusion in lactated Ringer's, ascorbate, and L-NAME treated microdialysis sites
Conditions Studied
Interventions
- DRUG Acetylcholine
- DRUG insulin aspart
Study Locations (1)
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2027-06-01 |
| Phase | Early Phase 1 |
What NCT05946785 shows while recruiting
NCT05946785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 321-participant average among 41 other Gestational Diabetes trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Gestational Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Acetylcholine is the first listed.
NCT05946785 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05946785 about?
NCT05946785 is a clinical study titled "Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes". The purpose of this investigation is to examine the role of oxidative stress in aberrant microvascular function in otherwise healthy women with a history of GDM.
What is the current status of trial NCT05946785?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2023-07-01. Estimated completion is 2027-06-01.
What conditions does trial NCT05946785 study?
This clinical trial studies the following conditions: Gestational Diabetes, Vascular Endothelial Function.
What interventions are being tested in trial NCT05946785?
The interventions under investigation include: Acetylcholine (DRUG), insulin aspart (DRUG).
Who is sponsoring clinical trial NCT05946785?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05946785 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gestational Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05946785's enrollment target sits among peer trials
28 36th of 41 higher than 5 of 41 other Gestational Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gestational Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes
RECRUITING · Early Phase 1
-
Soy Supplementation and Gestational Diabetes
COMPLETED · Early Phase 1
-
Nutrition Optimization and Community Upliftment for Postpartum Recovery
RECRUITING · NA
-
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI